APA (7th ed.) Citation

Wang, S., Chou, Y., Wen, K., Liew, P., Lu, Y., Chen, L., . . . Chu, L. (2025). Combined pembrolizumab and bevacizumab therapy in heavily treated recurrent ovarian cancer. European Journal of Gynaecological Oncology, 46(8), 48. https://doi.org/10.22514/ejgo.2025.108

Chicago Style (17th ed.) Citation

Wang, Shin-Yi, Yu-Ting Chou, Kuo-Chang Wen, Phui-Ly Liew, Yueh-Hsun Lu, Lin-Yu Chen, Pi-Lin Sung, Hung-Cheng Lai, and Ling-Hui Chu. "Combined Pembrolizumab and Bevacizumab Therapy in Heavily Treated Recurrent Ovarian Cancer." European Journal of Gynaecological Oncology 46, no. 8 (2025): 48. https://doi.org/10.22514/ejgo.2025.108.

MLA (9th ed.) Citation

Wang, Shin-Yi, et al. "Combined Pembrolizumab and Bevacizumab Therapy in Heavily Treated Recurrent Ovarian Cancer." European Journal of Gynaecological Oncology, vol. 46, no. 8, 2025, p. 48, https://doi.org/10.22514/ejgo.2025.108.